Drug Trial Radar · NCT02196831
Tesamorelin Effects on Liver Fat and Histology in HIV
Last checked: Nov 20, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jul 1, 2015
Primary completion
Jan 16, 2019
Study completion Jul 24, 2019
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jul 22, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection. Nonalcoholic steatohepatitis (NASH) is a more severe form of NAFLD in which increased liver fat is also accompanied by inflammation, cellular damage, and fibrosis. NAFLD is most prevalent in patients who also have increased visceral adiposity, and our group has previously shown that HIV-infected individuals with increased visceral adiposity generally have decreased growth hormone secretion. Tesamorelin is a growth hormone releasing hormone (GHRH) analogue that increases endogenous growth hormone secretion. Tesamorelin is FDA-approved for the reduction of visceral fat in HIV-infected individuals. In a previous study, treatment with tesamorelin in HIV-infected individuals selected for abdominal adiposity reduced liver fat. The current study is designed to test the effect of tesamorelin on liver fat and steatohepatitis in HIV-infected individuals who have NAFLD. The investigators hypothesize that tesamorelin will reduce liver fat and will also ameliorate the inflammation, fibrosis, and hepatocellular damage seen in conjunction with NASH.
Conditions
- Human Immunodeficiency Virus (HIV)
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
Interventions
tesamorelinDrug
PlaceboDrug
inactive substance that looks like tesamorelin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Liver Fat as Measured by 1-H Magnetic Resonance SpectroscopyTime frame: change between baseline and 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Institutes of Health
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.